@Article{096504019X15766663541105,
AUTHOR = {Zhiyi Peng, Guohong Cao, Qinming Hou, Ling Li, Shihong Ying, Junhui Sun, Guanhui Zhou, Jian Zhou, Xin Zhang, Wenbin Ji, Zhihai Yu, Tiefeng Li, Dedong Zhu, Wenhao Hu, Jiansong Ji, Haijun Du, Changsheng Shi, Xiaohua Guo, Jian Fang, Jun Han, Wenjiang Gu, Xiaoxi Xie, Zhichao Sun, Huanhai Xu, Xia Wu, Tingyang Hu, Jing Huang, Hongjie Hu, Jiaping Zheng, Jun Luo, Yutang Chen, Wenqiang Yu, Guoliang Shao},
TITLE = {The Comprehensive Analysis of Efficacy and Safety of CalliSpheres<sup>®</sup> Drug-Eluting Beads Transarterial Chemoembolization in  367 Liver Cancer Patients: A Multiple-Center, Cohort Study},
JOURNAL = {Oncology Research},
VOLUME = {28},
YEAR = {2020},
NUMBER = {3},
PAGES = {249--271},
URL = {http://www.techscience.com/or/v28n3/48530},
ISSN = {1555-3906},
ABSTRACT = {This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial 
chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer 
patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, 
including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 
55 secondary liver cancer cases. All the patients received CalliSpheres<sup>®</sup>
 DEB-TACE treatment. Treatment 
response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE 
treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR), with mean OS 
of 384 days [95% confidence interval (CI): 375–393 days]. CR and ORR were both higher in HCC patients compared with primary ICC patients and secondary liver cancer patients, while no difference was discovered 
in OS. Portal vein invasion was an independent risk factor for CR, while portal vein invasion, previous conventional TACE (cTACE) treatment, and abnormal blood creatinine (BCr) were independent risk factors for 
ORR. In addition, largest nodule size 5.0 cm, abnormal albumin (ALB), and abnormal total bilirubin (TBIL) 
independently correlated with unfavorable OS. Most liver function indexes were recovered to baseline levels 
at 1–3 months after DEB-TACE. Common AEs were pain, fever, vomiting, and nausea; most of them were at 
mild grade. CalliSpheres<sup>®</sup>
 DEB-TACE is efficient and well tolerated in Chinese liver cancer patients. Portal 
vein invasion, previous cTACE treatment, largest nodule size, abnormal BCr, ALB, and TBIL correlate with 
worse prognosis independently.},
DOI = {10.3727/096504019X15766663541105}
}